Roman Butler Fullerton & Co. Cuts Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Roman Butler Fullerton & Co. lessened its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 5.5% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 4,099 shares of the biopharmaceutical company’s stock after selling 240 shares during the quarter. Roman Butler Fullerton & Co.’s holdings in Gilead Sciences were worth $326,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Arrowstreet Capital Limited Partnership grew its stake in Gilead Sciences by 324.8% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 18,002,214 shares of the biopharmaceutical company’s stock worth $1,070,232,000 after purchasing an additional 13,764,169 shares in the last quarter. Morgan Stanley grew its stake in Gilead Sciences by 11.5% during the 4th quarter. Morgan Stanley now owns 17,196,950 shares of the biopharmaceutical company’s stock worth $1,476,358,000 after purchasing an additional 1,780,489 shares in the last quarter. Renaissance Technologies LLC grew its stake in Gilead Sciences by 70.6% during the 1st quarter. Renaissance Technologies LLC now owns 15,492,116 shares of the biopharmaceutical company’s stock worth $921,006,000 after purchasing an additional 6,410,047 shares in the last quarter. Bank of New York Mellon Corp grew its stake in Gilead Sciences by 14.8% during the 3rd quarter. Bank of New York Mellon Corp now owns 15,421,436 shares of the biopharmaceutical company’s stock worth $951,350,000 after purchasing an additional 1,987,058 shares in the last quarter. Finally, Northern Trust Corp grew its stake in Gilead Sciences by 3.0% during the 1st quarter. Northern Trust Corp now owns 14,969,251 shares of the biopharmaceutical company’s stock worth $889,922,000 after purchasing an additional 430,810 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

GILD has been the subject of several analyst reports. Wells Fargo & Company lowered their price objective on Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a research report on Monday, March 4th. Oppenheimer lowered their price objective on Gilead Sciences from $115.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, February 12th. Royal Bank of Canada lowered their price objective on Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating for the company in a research report on Wednesday, February 14th. Truist Financial cut Gilead Sciences from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $91.00 to $82.00 in a research report on Thursday, February 22nd. Finally, UBS Group lowered their price objective on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Gilead Sciences presently has an average rating of “Hold” and a consensus target price of $84.71.

Insider Buying and Selling at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the transaction, the insider now directly owns 96,304 shares of the company’s stock, valued at approximately $7,026,339.84. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 0.16% of the stock is owned by company insiders.

Gilead Sciences Stock Down 1.2 %

GILD opened at $66.16 on Friday. The business has a 50 day moving average price of $72.10 and a two-hundred day moving average price of $76.58. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08. The company has a market cap of $82.37 billion, a PE ratio of 14.70, a P/E/G ratio of 0.92 and a beta of 0.19. Gilead Sciences, Inc. has a 52 week low of $65.90 and a 52 week high of $87.86.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.72 EPS for the quarter, missing the consensus estimate of $1.76 by ($0.04). The company had revenue of $7.12 billion for the quarter, compared to analysts’ expectations of $7.10 billion. Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. The firm’s revenue was down 3.7% on a year-over-year basis. During the same period in the prior year, the company earned $1.67 earnings per share. As a group, research analysts anticipate that Gilead Sciences, Inc. will post 6.55 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Friday, March 15th were paid a dividend of $0.77 per share. The ex-dividend date of this dividend was Thursday, March 14th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.75. This represents a $3.08 annualized dividend and a yield of 4.66%. Gilead Sciences’s dividend payout ratio is currently 68.44%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.